Journal article

3-Year Freedom from Progression After Ga-68-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial

Louise Emmett, Reuben Tang, Rohan Nandurkar, George Hruby, Paul Roach, Jo Anne Watts, Thomas Cusick, Andrew Kneebone, Bao Ho, Lyn Chan, Pim J van Leeuwen, Matthijs J Scheltema, Andrew Nguyen, Charlotte Yin, Andrew Scott, Colin Tang, Michael McCarthy, Karen Fullard, Matthew Roberts, Roslyn Francis Show all

Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2020


68Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in men with biochemical recurrence (BCR) after radical prostatectomy (RP), but its longer-term prognostic or predictive potential in these men is unknown. The aim of this study was to evaluate the predictive value of PSMA PET for a 3-y freedom from progression (FFP) in men with BCR after RP undergoing salvage radiotherapy (sRT). Methods: This prospective multicenter study enrolled 260 men between 2015 and 2017. Eligible patients were referred for PSMA PET with a rising level of prostate-specific antigen (PSA) after RP. Management after PSMA PET was recorded but not mandated. PSMA PET protocols were standardize..

View full abstract

University of Melbourne Researchers